JP2017514843A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514843A5 JP2017514843A5 JP2016565482A JP2016565482A JP2017514843A5 JP 2017514843 A5 JP2017514843 A5 JP 2017514843A5 JP 2016565482 A JP2016565482 A JP 2016565482A JP 2016565482 A JP2016565482 A JP 2016565482A JP 2017514843 A5 JP2017514843 A5 JP 2017514843A5
- Authority
- JP
- Japan
- Prior art keywords
- drug delivery
- liquid crystalline
- delivery system
- crystalline drug
- api
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 claims 23
- 238000012377 drug delivery Methods 0.000 claims 20
- 239000008186 active pharmaceutical agent Substances 0.000 claims 16
- 208000030533 eye disease Diseases 0.000 claims 12
- 239000000243 solution Substances 0.000 claims 10
- 239000006185 dispersion Substances 0.000 claims 7
- 239000002105 nanoparticle Substances 0.000 claims 6
- 229920001451 polypropylene glycol Polymers 0.000 claims 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 5
- 229920001477 hydrophilic polymer Polymers 0.000 claims 5
- 150000002632 lipids Chemical class 0.000 claims 5
- 230000003232 mucoadhesive effect Effects 0.000 claims 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 239000007864 aqueous solution Substances 0.000 claims 3
- 239000004359 castor oil Substances 0.000 claims 3
- 229960003957 dexamethasone Drugs 0.000 claims 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 3
- 229960004875 difluprednate Drugs 0.000 claims 3
- 229960000289 fluticasone propionate Drugs 0.000 claims 3
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229960003702 moxifloxacin Drugs 0.000 claims 3
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 2
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 229920001503 Glucan Polymers 0.000 claims 2
- 229920002907 Guar gum Polymers 0.000 claims 2
- 206010029113 Neovascularisation Diseases 0.000 claims 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 2
- 229920000148 Polycarbophil calcium Polymers 0.000 claims 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 claims 2
- 229920002385 Sodium hyaluronate Polymers 0.000 claims 2
- 240000004584 Tamarindus indica Species 0.000 claims 2
- 235000004298 Tamarindus indica Nutrition 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 2
- 229960004099 azithromycin Drugs 0.000 claims 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 2
- 150000007980 azole derivatives Chemical class 0.000 claims 2
- 229940092705 beclomethasone Drugs 0.000 claims 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 2
- 229960002537 betamethasone Drugs 0.000 claims 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 2
- 208000010217 blepharitis Diseases 0.000 claims 2
- 229960004436 budesonide Drugs 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 2
- 229940105329 carboxymethylcellulose Drugs 0.000 claims 2
- 235000019438 castor oil Nutrition 0.000 claims 2
- 229960000541 cetyl alcohol Drugs 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 229960004544 cortisone Drugs 0.000 claims 2
- 229960004486 desoxycorticosterone acetate Drugs 0.000 claims 2
- 229960001259 diclofenac Drugs 0.000 claims 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 2
- 229960001048 fluorometholone Drugs 0.000 claims 2
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 claims 2
- 229960001469 fluticasone furoate Drugs 0.000 claims 2
- XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 2
- 239000000665 guar gum Substances 0.000 claims 2
- 235000010417 guar gum Nutrition 0.000 claims 2
- 229960002154 guar gum Drugs 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 206010023332 keratitis Diseases 0.000 claims 2
- 229960003744 loteprednol etabonate Drugs 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 229960004584 methylprednisolone Drugs 0.000 claims 2
- 229960001002 nepafenac Drugs 0.000 claims 2
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 claims 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- 229940044476 poloxamer 407 Drugs 0.000 claims 2
- 229920001992 poloxamer 407 Polymers 0.000 claims 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 2
- 229950005134 polycarbophil Drugs 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 229940068968 polysorbate 80 Drugs 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229960001589 posaconazole Drugs 0.000 claims 2
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 claims 2
- 230000002980 postoperative effect Effects 0.000 claims 2
- 229960002800 prednisolone acetate Drugs 0.000 claims 2
- 235000010413 sodium alginate Nutrition 0.000 claims 2
- 239000000661 sodium alginate Substances 0.000 claims 2
- 229940005550 sodium alginate Drugs 0.000 claims 2
- 229940010747 sodium hyaluronate Drugs 0.000 claims 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical group [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims 2
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims 2
- 229960002368 travoprost Drugs 0.000 claims 2
- 229960002117 triamcinolone acetonide Drugs 0.000 claims 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims 2
- 229960004224 tyloxapol Drugs 0.000 claims 2
- 229920001664 tyloxapol Polymers 0.000 claims 2
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 239000000230 xanthan gum Substances 0.000 claims 2
- 235000010493 xanthan gum Nutrition 0.000 claims 2
- 229920001285 xanthan gum Polymers 0.000 claims 2
- 229940082509 xanthan gum Drugs 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010065062 Meibomian gland dysfunction Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000001384 anti-glaucoma Effects 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 229960001777 castor oil Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 229960001798 loteprednol Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940057917 medium chain triglycerides Drugs 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 229960000808 netilmicin Drugs 0.000 claims 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 claims 1
- -1 polycarbopol Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 229960001487 rimexolone Drugs 0.000 claims 1
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 claims 1
- 238000010008 shearing Methods 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000009210 therapy by ultrasound Methods 0.000 claims 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461987012P | 2014-05-01 | 2014-05-01 | |
| US61/987,012 | 2014-05-01 | ||
| PCT/US2015/028748 WO2015168523A1 (en) | 2014-05-01 | 2015-05-01 | Membrane-adherent self-assembled systems for treatment of ocular disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514843A JP2017514843A (ja) | 2017-06-08 |
| JP2017514843A5 true JP2017514843A5 (enExample) | 2017-12-14 |
| JP6452725B2 JP6452725B2 (ja) | 2019-01-16 |
Family
ID=54359368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016565482A Active JP6452725B2 (ja) | 2014-05-01 | 2015-05-01 | 眼疾患の治療のための膜付着性の自己組織化システム |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9901544B2 (enExample) |
| EP (1) | EP3137481B1 (enExample) |
| JP (1) | JP6452725B2 (enExample) |
| KR (1) | KR101890503B1 (enExample) |
| CN (1) | CN106459137B (enExample) |
| AU (2) | AU2015252908B2 (enExample) |
| CA (1) | CA2946373C (enExample) |
| ES (1) | ES2924768T3 (enExample) |
| MY (1) | MY193694A (enExample) |
| NZ (1) | NZ725028A (enExample) |
| SG (1) | SG11201608729RA (enExample) |
| WO (1) | WO2015168523A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2706535T3 (es) * | 2016-07-07 | 2019-03-29 | Salvat Lab Sa | Composiciones oftálmicas que comprenden aceite de ricino y triglicéridos de cadena media |
| WO2018230713A1 (ja) * | 2017-06-16 | 2018-12-20 | 学校法人同志社 | カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用 |
| EP3639854B1 (en) | 2017-06-16 | 2026-01-07 | The Doshisha | Mtor-inhibitor-containing medicine for treating or preventing fuchs' endothelial corneal dystrophy |
| CN110785162B (zh) * | 2017-06-22 | 2023-08-01 | Ys生命科学株式会社 | 用于治疗青光眼的滴眼液组合物 |
| US11129862B2 (en) | 2017-08-30 | 2021-09-28 | Johnson & Johnson Consumer Inc. | Ophthalmic compositions |
| US11000530B2 (en) * | 2017-09-01 | 2021-05-11 | Murray And Poole Enterprises Ltd | Methods and compositions for the treatment of ophthalmic conditions |
| JP7056480B2 (ja) * | 2017-09-08 | 2022-04-19 | ライオン株式会社 | 眼科用組成物及び涙液油層安定化剤 |
| CN109316440B (zh) * | 2018-09-29 | 2020-12-29 | 华中科技大学 | 一种温敏性液晶纳米水凝胶及其制备方法与应用 |
| EP4233872B1 (en) * | 2018-10-24 | 2025-07-02 | Ferring B.V. | Mucoadhesive pharmaceutical compositions of corticosteroids |
| GB201818043D0 (en) * | 2018-11-05 | 2018-12-19 | Waterford Institute Of Tech | Artifical Tears |
| JP2023527162A (ja) * | 2020-05-18 | 2023-06-27 | マックス バイオロジー カンパニー リミテッド | 脂質ポリマー組成物及び使用方法 |
| US12102632B2 (en) | 2020-08-26 | 2024-10-01 | Somerset Therapeutics, Llc | Quinolone dispersions |
| US11382910B2 (en) * | 2020-08-26 | 2022-07-12 | Somerset Therapeutics, Llc. | Loteprednol and moxifloxacin compositions and methods |
| WO2022077060A1 (en) * | 2020-10-13 | 2022-04-21 | University Of South Australia | Antimicrobial compositions and methods of use |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716830B2 (en) * | 1998-09-30 | 2004-04-06 | Alcon, Inc. | Ophthalmic antibiotic compositions containing moxifloxacin |
| PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| JP4049216B2 (ja) * | 2003-05-09 | 2008-02-20 | ポーラ化成工業株式会社 | 液晶構造を有する製剤 |
| US20070020299A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| US20050235740A1 (en) * | 2004-04-27 | 2005-10-27 | Guido Desie | Method to improve the quality of dispersion formulations |
| CN101005828B (zh) * | 2004-06-17 | 2012-01-11 | 维尔恩公司 | 用于经粘膜递送活性成分的包含粘膜粘附蛋白和所述活性物质的组合物 |
| US20080145430A1 (en) * | 2004-12-08 | 2008-06-19 | Santipharp Panmai | Ophthalmic Nanoparticulate Formulation Of A Cyclooxygenase-2 Selective Inhibitor |
| CN101137370B (zh) * | 2005-02-09 | 2014-08-13 | 参天制药株式会社 | 用于治疗疾病或病症的液体制剂 |
| US8906392B2 (en) | 2005-12-16 | 2014-12-09 | University Of Kansas | Nanocluster compositions and methods |
| KR20090053892A (ko) * | 2006-07-25 | 2009-05-28 | 오스모티카 코프. | 점안액 |
| JP2010064995A (ja) * | 2008-09-12 | 2010-03-25 | Nikko Chemical Co Ltd | 外用消炎鎮痛剤組成物 |
| US8703922B2 (en) * | 2009-12-25 | 2014-04-22 | Chemgenesis Incorporated | Low-viscosity liquid crystal compound |
| CN101773670A (zh) * | 2009-12-29 | 2010-07-14 | 中山大学 | 一种液晶药物载体 |
| JP2012017318A (ja) * | 2010-06-07 | 2012-01-26 | Nikko Chemical Co Ltd | 液晶及びそれを含有する皮膚外用剤 |
| US8772273B2 (en) * | 2011-10-04 | 2014-07-08 | Quretino Therapeutics, Inc. | Formulations and uses of retinoic acid receptor selective agonists |
| NZ741873A (en) * | 2012-05-03 | 2019-04-26 | Kala Pharmaceuticals Inc | Pharmaceutical nanoparticles showing improved mucosal transport |
| EP3517541B1 (en) * | 2012-05-08 | 2020-07-15 | Nicox Ophthalmics, Inc. | Polymorphic form of fluticasone propionate |
| US8765725B2 (en) | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
-
2015
- 2015-05-01 CA CA2946373A patent/CA2946373C/en active Active
- 2015-05-01 NZ NZ725028A patent/NZ725028A/en unknown
- 2015-05-01 JP JP2016565482A patent/JP6452725B2/ja active Active
- 2015-05-01 EP EP15785661.8A patent/EP3137481B1/en active Active
- 2015-05-01 ES ES15785661T patent/ES2924768T3/es active Active
- 2015-05-01 SG SG11201608729RA patent/SG11201608729RA/en unknown
- 2015-05-01 US US15/308,000 patent/US9901544B2/en active Active
- 2015-05-01 AU AU2015252908A patent/AU2015252908B2/en active Active
- 2015-05-01 CN CN201580019868.9A patent/CN106459137B/zh active Active
- 2015-05-01 KR KR1020167030513A patent/KR101890503B1/ko active Active
- 2015-05-01 MY MYPI2016703941A patent/MY193694A/en unknown
- 2015-05-01 WO PCT/US2015/028748 patent/WO2015168523A1/en not_active Ceased
-
2018
- 2018-02-27 US US15/906,352 patent/US10603273B2/en active Active
- 2018-03-06 AU AU2018201596A patent/AU2018201596B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514843A5 (enExample) | ||
| JP6452725B2 (ja) | 眼疾患の治療のための膜付着性の自己組織化システム | |
| US20250049719A1 (en) | Dexamethasone prodrug compositions and uses thereof | |
| RU2747803C2 (ru) | Водная суспензия, содержащая наночастицы глюкокортикостероида | |
| JP2018039781A (ja) | 眼科用組成物 | |
| CN101757621B (zh) | 一种眼部抗炎的环糊精包合药物组合物 | |
| KR20140124405A (ko) | 붕산을 포함하는 자기-보존 오일 분산제 | |
| TWI620578B (zh) | 用以減少眼用類固醇的倂發症之藥學組成物 | |
| TWI756168B (zh) | 多微泡及其眼瞼投予 | |
| JP2015526467A5 (enExample) | ||
| JP2015506983A5 (enExample) | ||
| JP6861634B2 (ja) | 眼疾患を処置するための組成物及び方法 | |
| JP2017501184A (ja) | 低減された眼圧で術後の炎症を治療するための方法 | |
| WO2020240451A1 (en) | In-situ gelling nanoemulsion of brinzolamide | |
| JP2006225323A (ja) | 水性外用組成物 | |
| CN109984995A (zh) | 一种伊维菌素纳米乳注射液及其制备方法 | |
| WO2025144421A1 (en) | Aqueous nanomicelle ophthalmic formulations containing difluprednate | |
| WO2017007609A1 (en) | Ocular treatment with reduced intraocular pressure | |
| EP3851097A1 (en) | Controlled release formulations | |
| HK1234413B (zh) | 用於治療眼部病症的膜附著性自組裝體系 | |
| HK1234413A1 (en) | Membrane-adherent self-assembled systems for treatment of ocular disorders |